Necrotic plaques in an elderly male

Bindi Gaglani, Ian Logan and Faris Kubba
Department of Dermatology, Ealing Hospital, Southall, UB1 3HW, UK
Corresponding author: Bindi Gaglani. Email: bindigaglani@hotmail.com

Introduction
Reactive perforating collagenosis may present in a giant form in elderly patients in the absence of end stage renal failure.

Case report
An 87-year-old male was admitted to the medical ward with sepsis secondary to a lower respiratory tract infection. He was subsequently referred to dermatology for a review of generalised pruritus associated with development of increasing numbers of generalised purulent and necrotic plaques (Figure 1). History was unobtainable due to sepsis-related delirium but the lesions were noted to have started after admission two months ago. He had a history of hypertension, atrial fibrillation, ischemic heart disease, treated pulmonary tuberculosis, type 2 diabetes and diabetic nephropathy (Chronic Kidney Disease stage 3a) with a pacemaker in situ. His medications included Apixaban, Amiloride, Nifedipine and Bumetanide.

Examination revealed well-defined disseminated symmetrical large round and oval plaques with areas of exposed dermis and subcutis ranging from 10 mm to 45 mm on erythematous bases. The older plaques had necrotic centres with evidence of purulent exudate from newer lesions over the back (Figure 2).

Blood tests showed raised inflammatory markers, stable renal function and a normal autoimmune screen. An echocardiogram ruled out infective endocarditis as a cause of the skin changes.

A 4 mm punch biopsy demonstrated mild hyperkeratosis with necroinflammatory exudate, erosion and subepidermal clefing, neutrophil extravasation in the upper dermis and evidence of perforating elastic fibres by Elastic van Gieson and trichrome stains (Figure 2).

What is your diagnosis?
Giant perforating collagenosis and elastosis.

Summary
Reactive perforating collagenosis is commonly recognised as an unusual form of transepithelial elimination of collagen and elastin fibres which are extruded through the epidermis in patients with a genetic predisposition or underlying diseases, such as diabetes mellitus or renal diseases.

Giant Acquired Reactive Perforating Collagenosis should be considered in the differential diagnosis of ulcerative plaque lesions of larger sizes compared to the usual size ranging between 2 and 8 mm and the largest lesions have been noted to be 2 cm.1–3

Definition and classification
Due to the complexity of perforating disorders, it was suggested to classify the disease as follows: (i) perforation as an incidental histological finding; (ii) secondary perforation (e.g. in granuloma annulare, pseudoxanthoma elasticum and chondrodermatitis nodularis chronica helicis) and (iii) primary perforating dermatoses.1

Primary perforating dermatosis is used as an umbrella term for four different entities: Elastosis Perforans Serpiginosa, Acquired Reactive Perforating Collagenosis, Perforating Folliculitis and Kyrle’s disease.1
Causes and genetics

An interaction of keratinocytes with altered structural proteins is likely to be the triggering factor to develop reactive perforating dermatosis. Elastin receptor 67-kDa overexpression in Elastosis Perforans Serpiginosa and Transforming growth factor beta (TGF-β3), Matrix metalloproteinase 1 (MMP-1) and Tissue inhibitor of metalloproteinase 1 (TIMP-1) overexpression in Acquired Reactive Perforating Collagenosis, indicate changes in extracellular matrix composition.\(^1\)

There have been reports of Acquired Reactive Perforating Collagenosis in a paraneoplastic form secondary to underlying solid organ and hematological malignancies.\(^2,4\)

Acquired Reactive Perforating Collagenosis may be associated with use of immunotherapeutic agents including epidermal growth factor receptor inhibitors (tyrosine kinase-i) including Erlotinib, Sorafenib and Lenvatinib and use of Ranibizumab (anti-angiogenic monoclonal antibody used in wet age-related macular degeneration).\(^5,6\)

Dermatoscopic features

Ormerod et al. analysed some dermatoscopic features of reactive perforating collagenosis which included a hyperkeratotic plug appearing as yellow brown structureless areas surrounded by an erythematous rim of inflammation.\(^7\)
Treatment options

Reactive perforating collagenosis may be self-limiting with spontaneous resolution over months. However, when significantly symptomatic and leading to a poor quality of life or complications, treatments have been trialled. It is a general understanding that underlying disease should be controlled alongside dermatological treatment for successful management. Topical potent steroids are the first-line treatment options but in case of failure successful treatment with phototherapy with Narrow Band UVB/PUVA has been reported. Topical benzoyl peroxide, topical isotretinoin gel 0.1% OD and improvement with oral allopurinol and oral acitretin (suggestive of follicular plugging being the initial pathogenesis) have been reported. In case of biologics causing the disease, when these have been stopped, the disease shows complete reversal.

Learning points

- Giant acquired reactive perforating collagenosis should be considered in the differentials of all hyperkeratotic plaques or in disseminated ulceration in patients with diabetes with renal impairment.
- With the advent of newer immunotherapy agents, it may be possible that more of these cases may be seen over time as a side-effect of treatment.
- It should also be considered as a paraneoplastic phenomenon in the absence of a history of diabetes or renal impairment.

MCQs

1. What are the 2 most common associations with Acquired reactive perforating collagenosis?
   (a) Diabetes and renal impairment
   (b) Hypothyroidism and diabetes
   (c) Hypertension and hypothyroidism
   (d) Infective endocarditis

2. Which one of these drugs can cause Acquired Reactive Perforating Collagenosis?
   (a) Warfarin
   (b) Tyrosine kinase inhibitors
   (c) Metformin
   (d) Topical steroids

Declarations

Competing Interests: None declared.
Funding: None declared.
Ethics approval. Written informed consent for publication was obtained from the patient.
Guarantor: BG
Contributorship: BG wrote the initial draft. BG and IL were responsible for patient care. IL contributed to the text. FK interpreted the pathology images and reports. All authors have seen and approved the final version of case report.
Acknowledgements: We sincerely thank our patient for his cooperation.
Provenance: Submitted; peer reviewed by Teerajet Taechameekietichai.

References

1. Schreml S, Hafner C, Eder F, Landthaler M, Burgdorf W, Babillas P. Kyre disease and acquired perforating collagenosis secondary to chronic renal failure and diabetes mellitus. *Case Rep Dermatol* 2011; 3: 209–211.
2. Kim RH, Kwa M, Adams S, Meehan SA, Stein JA. Giant acquired reactive perforating collagenosis in a patient with diabetes mellitus and metastatic breast carcinoma. *JAAD Case Rep* 2016; 2: 22-24.
3. Schreml S, Hafner C, Eder F, Landthaler M, Burgdorf W, Babillas P. Kyre disease and acquired perforating collagenosis secondary to chronic renal failure and diabetes mellitus. *Case Rep Dermatol* 2011; 3: 209–211.
4. Rivera-Rodrı́guez A, Prieto-Torres L, Felipo-Berlanga F, Ara-Martı́n M. Acquired reactive perforating collagenosis associated with Hodgkin disease. Clin Exp Dermatol 2017; 42: 934–936.

5. Sato-Sano M, Cury-Martins J, Macarenco R, Domingues RB, Vasconcelos R, Sanches JA. Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib. J Dtsch Dermatol Ges 2018; 16(12): 1486–1489.

6. Lederhandler M, Beasley JM, Brinster NK, Nagler AR. Unusual eruption in association with sorafenib: a case of acquired perforating dermatosis, reactive perforating collagenosis type. Dermatol Online J 2018; 24: 13030/qt8b40k5kg.

7. Ormerod E, Atwan A, Intzedy L, Stone N. Dermoscopy features of acquired reactive perforating collagenosis: a case series. Dermatol Pract Concept 2018; 8: 303–305.